Subsequently, the clinical results of 66 cancer patients after DC-WT1 vaccination, including thirty AML patients who were at very high risk of relapse, were reported (Table 2, NCT00965224), which proved that WT1-targeted DC-based vaccination is an effective immunotherapeutic strategy to prevent relapse in AML patients (Anguille et al., 2017). This evidence concerns the gene WT1 and acute myeloid leukemia.